Douglas Dieterich, MD
- PROFESSOR | Medicine, Liver Diseases
Specialties:Liver Medicine, Gastroenterology
Dr. Dieterich is currently Professor of Medicine in the Division of Liver Diseases and also Director of Continuing Medical Education in the Department of Medicine at Mount Sinai School of Medicine, New York, NY.
He has a triple appointment in the divisions of Liver Disease, Gastroenterology, and Infectious Diseases.
Douglas T. Dieterich graduated from Yale University in New Haven, CT and received his Doctorate of Medicine from New York University of Medicine in NY. He completed his internship and residency in Internal Medicine at the Bellevue Hospital Center in New York, NY where he was also a fellow in the Division of Gastroenterology. He became Clinical Assistant Professor of medicine and then a Clinical Professor of Medicine, both at the New York University. He remains as an Adjunct Clinical Professor of Medicine at New York University School of Medicine.
Dr. Dieterich is an investigator for many ongoing clinical trials evaluating the safety and efficacy of new antiviral treatments for chronic hepatitis B & C.
Dr. Dieterich is a member of many professional societies and is a fellow of both the American College of Physicians and the American College of Gastroenterology. He has served on several committees of the AIDS Clinical Trials Group at the National Institutes of Health (NIH), including the Steering Committee of the Opportunistic Infections Core Committee and the Cytomegalovirus (CMV) Committee. He was Chair and Co-Chair, respectively, of the Enteric Parasites Committee and the Protozoan Committee. He also served on the NIH Study Sections for CMV and cryptosporidiosis.
Widely published, Dr. Dieterich is the author of numerous journal articles, abstracts and book chapters on viral hepatitis and AIDS associated infections of the gastrointestinal tract and liver.
In the News:
Dr. Dieterich discusses Why The Benefits of Hepatitis C Drug Therapies Outweigh The Risks
Dr. Dieterich discusses viral hepatitis in The Daily News feature The Daily Check Up.
View the PDF
Dr. Dieterich discusses the advancements in the treatment of Hepatitis C in The Daily News Feature, The Daily Check Up.
American Board of Internal Medicine
- Colon Polypectomy
- Colon Polyps
- Esophageal Variceal Injection
- Esophageal Varices
- Flexible Sigmoidoscopy
- Gilbert's Syndrome
- HIV Coinfection in Viral Hepatitis
- Hepatitis A
- Hepatitis A Vaccine
- Hepatitis B
- Hepatitis B Vaccine
- Hepatitis C
- Liver Biopsy
- Toxic Hepatitis
- Upper GI Endoscopy
- Wilson's Disease
MD, New York University School of Medicine
Fellowship, Gastroenterology, NYU Medical Center
- An Open-Label Multicenter Study to Evaluate Long-term Outcomes with ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ II)
The purpose of this study is to evaluate the effect of a reduced amount of HCV in a subject's blood on long-term clinical outcomes with study drugs in subjects with genotype 1 chronic hepatitis C virus (HCV) Infection.
Subjects will receive the study drugs ABT-450/r/...
- Phase I, Randomized, Open-Label, Active-Controlled, Dose Escalation Study to Evaluate the Safety, Tolerability, and Immunogenicity of INO-1800 Alone or in Combination With INO-9112 Delivered IM Followed by Electroporation in Select Nucleos(t)ide Analogue-treated, Chronic Hepatitis B Patients
The purpose of this study is to see how safe two investigational study agents (INO-1800 and INO-9112)are when used in people with chronic Hepatitis B infection. The investigational agents will be administered to subjects using an investigational device (called CELLECTRA®). Thi...
Dieterich DT. Treatment of Hepatitis C and Anemia in Human Immunodeficiency Virus-Infected Patients. J Infect Dis 2002; 185(suppl 2): S128-S137.
Soriano V, Sulkowski M, Bergin C, Hatzakis A, Cacoub P, Katlama C, Cargnel A, Mauss S, Dieterich D, Moreno S, Ferrari C, Poynard T, Rockstroh J. Care of Patients with Chronic hepatitis C and HIV co-infection: recommendations from the HIV-HCV International Panel. AIDS 2002; 16: 813-828.
Palmon R, Koo BC, Shoultz DA, Dieterich DT D. Lack of Hepatotoxicity Associated with Nonnucleoside Reverse Transcriptase Inhibitors. J Acquir Immune Defic Syndr 2002; 29: 340-345.
Dieterich DT. Human Immunodeficiency Virus and the Liver: Lessons Learned and Still be Learned. Seminars in Liver Disease 2003; 23(2): 107-114.
Dieterich DT. HIV and Hepatitis B Virus: Options for Managing Coinfection. Topics in HIV Medicine 2003; 11(1): 16-19.
Nickolas K, Dieterich DT. Toxicity of Non-Nucleoside Analogue Reverse Transcriptase Inhibitors . Seminars in Liver Disease 2003; 23(2): 173-182.
Dieterich DT. Managing Antiretroviral-Associated Liver Disease . Journal of Acquired Immune Deficiency Syndromes; 22.